DDInter1627 DDInter233
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Rufinamide {u} (Compound) binds {v} (Gene) SCN2A
SCN2A {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Midazolam
Midazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rufinamide {u} (Compound) binds {v} (Gene) SCN2A
SCN2A {u} (Gene) is bound by {v} (Compound) Zonisamide
Zonisamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rufinamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Rufinamide {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rufinamide {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Gefitinib
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rufinamide {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Rufinamide {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Rufinamide {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Brigatinib
Rufinamide (Compound) binds SCN2A (Gene) and SCN2A (Gene) is bound by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Brigatinib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rufinamide (Compound) binds SCN2A (Gene) and SCN2A (Gene) is bound by Zonisamide (Compound) and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rufinamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Rufinamide (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rufinamide (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rufinamide (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Rufinamide (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Brigatinib
Rufinamide (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Chloramphenicol (Compound) and Chloramphenicol may lead to a major life threatening interaction when taken with Brigatinib